Validation of AdnaTest BreastCancer


"Determination of HER2-antigen in serum of initially HER2-negative metastasized breast cancer patients"

(With consideration of the HER2 mRNA expression of circulating tumor cells.)

1. Aim
This pilot type study is performed to determine the prognostic value of the AdnaTest BreastCancer in CTC as non-invasive diagnostic to predict clinical prognosis in advanced breast cancer and in addition to provide a decision guidance for therapy administration with Herceptin.
2. Features
Patients are recruited in a single center. Inclusion criteria are advanced breast cancer (M1) with initially HER2 negative or HER2 unknown primary tumor. Patient data are processed as follows: not regulated (ICH-GCP), non-randomised, open labeled and prospective. HER2 mRNA expression in circulating tumor cells is analyzed by the AdnaTest BreastCancer.
3. Cooperating Center
University of Tübingen, Germany, Gynecological Hospital - Prof. Dr. E.-F. Solomayer, Prof. Dr. T. Fehm

Recruitment and data collection are completed. Results are published.

Determination of HER2 status using both serum HER2 levels and circulating tumor cells in patients with recurrent breast cancer whose primary tumor was HER2 negative or of unknown HER2 status   >>Download


"Detection of circulating tumor cells as a predictive factor in therapy monitoring"

Molecular profiling and predictive value of circulating tumor cells in patients with metastatic breast cancer: an option for monitoring response to breast cancer related therapies


"EMT and stem cell characteristics of circulating tumor cells"

Identification of a stem cell marker and markers involved in epithelial-mesenchymal transition on circulating tumor cells in patients with metastatic breast cancer   >>Download